Combination Therapy With the Proteasome Inhibitor Carfilzomib for the Antibody-Mediated Rejection Diagnosis in Lung Transplantation Trial (PICARD-Lung)

Trial Profile

Combination Therapy With the Proteasome Inhibitor Carfilzomib for the Antibody-Mediated Rejection Diagnosis in Lung Transplantation Trial (PICARD-Lung)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Mar 2017

At a glance

  • Drugs Carfilzomib (Primary)
  • Indications Lung transplant rejection
  • Focus Therapeutic Use
  • Acronyms PICARD-Lung
  • Most Recent Events

    • 20 Sep 2016 Status changed from active, no longer recruiting to recruiting.
    • 23 Dec 2015 Status changed from not yet recruiting to active, no longer recruiting as per ClinicalTrials.gov record
    • 26 Jun 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top